0IDA Stock Overview
Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States.
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for 0IDA from our risk checks.
Dynavax Technologies Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$11.23 |
| 52 Week High | US$15.15 |
| 52 Week Low | US$10.23 |
| Beta | 1.28 |
| 1 Month Change | -6.49% |
| 3 Month Change | -19.67% |
| 1 Year Change | 2.04% |
| 3 Year Change | 19.60% |
| 5 Year Change | n/a |
| Change since IPO | -35.09% |
Recent News & Updates
Recent updates
Shareholder Returns
| 0IDA | GB Biotechs | GB Market | |
|---|---|---|---|
| 7D | -6.9% | -2.3% | -0.7% |
| 1Y | 2.0% | -29.4% | -1.8% |
Return vs Industry: 0IDA exceeded the UK Biotechs industry which returned -29.6% over the past year.
Return vs Market: 0IDA exceeded the UK Market which returned -2.4% over the past year.
Price Volatility
| 0IDA volatility | |
|---|---|
| 0IDA Average Weekly Movement | 3.7% |
| Biotechs Industry Average Movement | 7.5% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in GB Market | 11.5% |
| 10% least volatile stocks in GB Market | 2.6% |
Stable Share Price: 0IDA's share price has been volatile over the past 3 months.
Volatility Over Time: 0IDA's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1996 | 408 | Ryan Spencer | www.dynavax.com |
Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe. The company also manufactures and sells CpG 1018, the adjuvant used in HEPLISAV-B.
Dynavax Technologies Corporation Fundamentals Summary
| 0IDA fundamental statistics | |
|---|---|
| Market cap | US$1.48b |
| Earnings (TTM) | -US$6.39m |
| Revenue (TTM) | US$232.28m |
6.4x
P/S Ratio-232.3x
P/E RatioIs 0IDA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 0IDA income statement (TTM) | |
|---|---|
| Revenue | US$232.28m |
| Cost of Revenue | US$102.48m |
| Gross Profit | US$129.81m |
| Other Expenses | US$136.19m |
| Earnings | -US$6.39m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.049 |
| Gross Margin | 55.88% |
| Net Profit Margin | -2.75% |
| Debt/Equity Ratio | 35.8% |
How did 0IDA perform over the long term?
See historical performance and comparison